What is the recommended dilution for intravenous administration of polymyxin B (Polymyxin B)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 31, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Recommended Dilution for Intravenous Administration of Polymyxin B

For intravenous administration of polymyxin B, dissolve 500,000 units in 300 to 500 mL of 5% Dextrose Injection for continuous drip infusion. 1

Dosing Recommendations

Standard Dosing

  • For adults and children with normal renal function, administer 15,000 to 25,000 units/kg body weight/day 1
  • A loading dose of 2-2.5 mg/kg is recommended, followed by a maintenance dose of 1.5-3 mg/kg/day divided into 2 doses 2
  • Infusions may be given every 12 hours, but the total daily dose must not exceed 25,000 units/kg/day 1
  • A 4-hour infusion is suggested to optimize pharmacokinetic/pharmacodynamic properties 2

Special Populations

  • For infants with normal kidney function, up to 40,000 units/kg/day may be administered without adverse effects 1
  • For patients with renal impairment, reduce the dose from 15,000 units/kg downward 1
  • For patients on continuous renal replacement therapy (CRRT), dosage adjustments are not necessary for polymyxin B 2, 3

Administration Considerations

Preparation

  • Dissolve 500,000 polymyxin B units in 300 to 500 mL of 5% Dextrose Injection for continuous drip infusion 1
  • In the interest of safety, solutions for parenteral use should be stored under refrigeration 1
  • Any unused portions should be discarded after 72 hours 1

Monitoring

  • Monitor renal function closely during polymyxin B therapy 3, 4
  • Be vigilant for early signs of nephrotoxicity, including albuminuria, cellular casts, azotemia, and diminishing urine output 3
  • Watch for neurological adverse events such as perioral paresthesia, dizziness, and numbness of extremities, which are common but typically resolve without treatment 5

Clinical Considerations

Pharmacokinetics

  • Polymyxin B is predominantly eliminated by non-renal pathways (median urinary recovery of only 4.04%) 6
  • Unlike colistin, polymyxin B clearance does not show any relationship with creatinine clearance (r² = 0.008) 6
  • The volume of distribution is approximately 0.219 L/kg, and the half-life is around 5.44 hours 5

Advantages Over Colistin

  • Polymyxin B may be associated with a lower incidence of renal failure compared to colistin 2, 3
  • Polymyxin B is available for direct intravenous administration and not as an inactive prodrug (unlike colistin) 2
  • Polymyxin B requires less dose adjustment than colistin in renal impairment 4

Cautions and Contraindications

  • Avoid concurrent use of other nephrotoxic medications when possible 3
  • Discontinue NSAIDs during polymyxin B treatment, as they can exacerbate kidney injury 3
  • Avoid the combination of NSAIDs, diuretics, and ACE inhibitors/ARBs during polymyxin B treatment as this dramatically increases acute kidney injury risk 3

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Management of Polymyxin-Associated Acute Kidney Injury (AKI)

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Colistin and Polymyxin B Differences

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Population pharmacokinetics of intravenous polymyxin B in critically ill patients: implications for selection of dosage regimens.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2013

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.